Acadia Pharma (ACAD)
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in Nor...
- Open
- 29.260
- High
- 29.830
- Low
- 29.150
- Prev. Close
- 29.580
- Volume
- 879.34K
- Turnover
- 26.08M
- Avg Price
- 29.661
- Bid/Ask Ratio
- --
- Amplitude
- 2.30%
- 52wk High
- 30.960
- Volume Ratio
- 0.69
- Turnover Ratio
- 0.69%
Acadia Pharma Analyst Rating
View moreForecast & Rating
Aug 25, 2026Price forecast
$34.0014.36%
Forecast & RatingBuy
21analysts
- Strong buy57.14%
- Buy19.05%
- Hold19.05%
- Sell4.76%
- Strong sell0.00%
News
- Market Beat · 2 days ago, 10:42 AM
Citigroup Increases ACADIA Pharmaceuticals (NASDAQ:ACAD) Price Target to $40.00
- StockTitan · Aug 23 at 06:01 PM
European Commission Approves DAYBU® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union | ACAD Stock News
- Market Beat · Aug 17 at 04:36 AM
GSA Capital Partners LLP Makes New Investment in ACADIA Pharmaceuticals Inc. $ACAD
- rttnews · Aug 13 at 03:30 AM
Biotech Stocks At 52-Week Highs - BIVI +22%, XNCR, ANRO, HAE, ACAD
- Market Beat · Aug 12 at 02:04 PM
ACADIA Pharmaceuticals Expands DAYBUE, NUPLAZID Reach Ahead of Key Alzheimer’s Data
- Quartr · Aug 12 at 01:41 PM
ACAD: DAYBUE STIX is quickly overtaking the original formulation as European launch preparations advance
